Arcus Biosciences, Inc.
RCUS
$22.43
$0.220.99%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 33.00M | 26.00M | 160.00M | 28.00M | 26.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 33.00M | 26.00M | 160.00M | 28.00M | 26.00M |
| Cost of Revenue | 121.00M | 141.00M | 139.00M | 122.00M | 101.00M |
| Gross Profit | -88.00M | -115.00M | 21.00M | -94.00M | -75.00M |
| SG&A Expenses | 26.00M | 27.00M | 29.00M | 28.00M | 28.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 147.00M | 168.00M | 168.00M | 150.00M | 129.00M |
| Operating Income | -114.00M | -142.00M | -8.00M | -122.00M | -103.00M |
| Income Before Tax | -106.00M | -135.00M | 0.00 | -112.00M | -93.00M |
| Income Tax Expenses | -- | -- | -- | -- | 1.00M |
| Earnings from Continuing Operations | -106.00M | -135.00M | 0.00 | -112.00M | -94.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.00M | -135.00M | 0.00 | -112.00M | -94.00M |
| EBIT | -114.00M | -142.00M | -8.00M | -122.00M | -103.00M |
| EBITDA | -111.00M | -140.00M | -6.00M | -119.00M | -100.00M |
| EPS Basic | -0.89 | -1.27 | -1.14 | -1.14 | -1.03 |
| Normalized Basic EPS | -0.56 | -0.79 | 0.00 | -0.71 | -0.63 |
| EPS Diluted | -0.89 | -1.27 | -1.14 | -1.14 | -1.03 |
| Normalized Diluted EPS | -0.56 | -0.79 | 0.00 | -0.71 | -0.63 |
| Average Basic Shares Outstanding | 118.50M | 106.50M | 106.10M | 98.40M | 91.70M |
| Average Diluted Shares Outstanding | 118.50M | 106.50M | 106.50M | 98.40M | 91.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |